Adverum Biotechnologies

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Adverum Biotechnologies sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 3 currently recruiting 4 completed early-phase tilt top decile by trial count

Adverum Biotechnologies: 10 sponsored US clinical trials, 3 recruiting.

Adverum Biotechnologies sponsors 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Wet AMD, with 2 trials.

Top-decile sponsor footprint

Adverum Biotechnologies ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

NCT07630649
RECRUITING Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

NCT07482176
RECRUITING Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

NCT06856577
ACTIVE NOT RECRUITING Phase 2

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

NCT05536973
ACTIVE NOT RECRUITING

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

NCT05607810
ACTIVE NOT RECRUITING

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

NCT04645212
COMPLETED Phase 2

ADVM-022 Intravitreal Gene Therapy for DME

NCT04418427
COMPLETED

Long-Term Follow-up Study of ADVM-043

NCT03804021
COMPLETED Phase 1

ADVM-022 Intravitreal Gene Therapy for Wet AMD

NCT03748784
COMPLETED Phase 1

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

NCT02168686

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 2

Therapeutic Areas

Wet AMD 2
Neovascular Age-related Macular Degeneration (nAMD) 2
Neovascular Age-related Macular Degeneration 2
Wet Age-related Macular Degeneration 1
Diabetic Macular Edema 1
Diabetic Retinopathy 1
Alpha-1 Antitrypsin Deficiency 1

What is open in the Adverum Biotechnologies pipeline

3 recruiting of 10 indexed (30% open); 4 completed (40%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Wet AMD (2 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Adverum Biotechnologies: open-pipeline peers nationwide

Peers matched on 10 registered trials and 30% open enrollment, not the therapeutic-area sidebar.

Adverum Biotechnologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 9.99.91010.1 0%10%20%30%40% Total trials Recruiting share Adverum BiotechnologiesAdamas PharmaceuticalsAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAimmune TherapeuticsCentre hospitalier de l'Université de Montréal (CHUM)Child TrendsJacques E. ChellyJason Sperry
Adverum Biotechnologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Adverum Biotechnologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 30% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Adverum Biotechnologies page

10 registered trials is a research-attention snapshot, not an endorsement of Adverum Biotechnologies or any single study.

  • 3 of Adverum Biotechnologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Wet AMD is the condition Adverum Biotechnologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Wet AMD trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Adverum Biotechnologies pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.